videoSlug

VideoSlug_VideoQuery

slug

VideoPageContentQuery

content

videos

query VideoSlug_VideoQuery(
  $videoSlug: String!
) {
  ...VideoPageContentQuery_1X4EH4
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  createdAt
  changedAt
  isPremium
  authors {
    __typename
    name
    pageUrl
    id
  }
  companies {
    name
    id
  }
  tags {
    name
    id
  }
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment LatestVideos_Videos on Query {
  videos(first: 5, upcoming: false, order: {field: liveTime, direction: DESC}) {
    edges {
      node {
        id
        title
        lang
        pageUrl
        liveTime
        isLive
        companies {
          name
          squareLogoUrl
          id
        }
      }
    }
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment VideoPageContentQuery_1X4EH4 on Query {
  content(slug: $videoSlug, type: [VIDEO, WEBCAST]) {
    __typename
    id
    title
    slug
    lang
    htmlBody
    isPremium
    summary
    companies {
      viewerIsFollowing
      id
      name
      pageUrl
      defaultInstrument {
        id
        isin
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    createdAt
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    ... on Video {
      imgUrl
      videoEmbedUrl(location: "inderes")
      audioEmbedUrl
      registrationInfoHtml
      registrationUrl
      liveTime
    }
    ... on Webcast {
      imgUrl
      videoEmbedUrl(location: "inderes")
      registrationInfoHtml
      registrationUrl
      liveTime
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
  }
  ...LatestVideos_Videos
}


type

__typename

title

lang

htmlBody

isPremium

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

changedAt

first

order

upcoming

edges

Oncopeptides

Language: en Sector: Health care - Pharmaceuticals & Biotechnology Activity: PressconferenceOncopeptides hereby announces that the Board of Directors has decided to carry out a fully guaranteed...

<div><p><strong>Language:</strong> en<br>
<strong>Sector:</strong> Health care - Pharmaceuticals &amp; Biotechnology<br>
<strong>Activity:</strong> Pressconference</p><div><p>Oncopeptides hereby announces that the Board of Directors has decided to carry out a fully guaranteed new share issue of approximately SEK 300 million with preferential rights for the Company&#x2019;s existing ordinary shareholders (the &#x201c;Rights Issue&#x201d;), subject to approval by an extraordinary general meeting which is planned to be held on 15 April 2024. The purpose of the Rights Issue is primarily to finance the ongoing commercialization of Pepaxti&#xae; in Europe until the Company expects to become cash flow positive by the end of 2026.&#xa0;</p>

<p>For more information click&#xa0;<a href="https://oncopeptides.com/en/media/press-releases/">here</a>.&#xa0;</p>
</div></div>

Inderes

Oncopeptides, Investor call, 2024

Demant

Genmab

Novonesis

HCA Morgenbørs 14/04 - Markedet forsøger at løfte sig 

Carasent

Carasent, Audiocast, Q1'26

Revenio Group

Revenio’s press conference on the Visionix acquisition

Flügger Group

Rockwool

Coloplast

Torm

Hafnia

North Media

HCA Morgenbørs 13/04 - Ingen USA/Iran-aftale var nok ventet, men Trump's deadline er en presbold

Recent videos